Even though a large volume of data supports the use of antiplatelet therapy in patients with ACS, there always remains an uncertainty regarding the optimal duration of therapy. In this exclusive KOL interview, Dr. Bhaskar Shah discusses anti-platelet drug selection in ACS and MI and the duration of therapy. Dr.
Bhaskar Shah practices at Jupiter Hospital in Thane West, Thane. Actively involved in more than 25,000 cardiac catheterization laboratory procedures during last 20 years. Director founder member, Consultant, and Interventional Cardiologist at Asian Heart Institute (2002-2007).
